Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. (Q47784587)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

1 reference

Yuichiro Yoshioka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Keisuke Uehara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tomoki Ebata

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yukihiro Yokoyama

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ayako Mitsuma

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Masato Nagino

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yukio Ando

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

14 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1300-1306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

"Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-013-0686-2

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases

21 January 2018

1 reference

12 December 2020

Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients

1 reference

12 December 2020

Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer

1 reference

12 December 2020

Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case

1 reference

12 December 2020

Delayed bile leak with avastin after liver resection for metastatic colorectal cancer

1 reference

12 December 2020

10.1007/S00595-013-0686-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23942819%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference